B6-hCALCA Mouse
Product Name
B6-hCALCA Mouse
Product ID
C001523
Strain Name
C57BL/6JCya-Calcaem1(hCALCA)/Cya
Backgroud
C57BL/6JCya
When using this mouse strain in a publication, please cite “B6-hCALCA Mouse (Catalog C001523) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
Gene Alias
CT, KC, PCT, CGRP, CALC1, CGRP1, CGRP-I, CGRP-alpha
NCBI ID
Chromosome
Chr 11
MGI ID
Datasheet
Strain Description
Calcitonin-related polypeptide alpha (CALCA) is a protein-encoded gene, also known as CALC1, CGRP, or CGRP-α. Multiple genetic factors and epigenetic modifications regulate CALCA gene expression, and it forms peptide hormones calcitonin (CT), α-isoform of calcitonin gene-related peptide (CGRP), and katacalcin through tissue-specific RNA alternative splicing and non-active precursor protein cleavage in transcription and translation. Calcitonin is synthesized and secreted by thyroid parafollicular cells, mainly involved in regulating calcium levels and phosphorus metabolism in bones and kidneys. It can reduce the concentration of calcium and phosphorus in the plasma and inhibit the absorption of calcium and phosphorus. CGRP mainly acts as a vasodilator and antimicrobial peptide, which can cause dilatation of coronary arteries, cerebral vessels, and systemic vessels, and help to regulate blood pressure. CGRP is also widely distributed in the pain pathways of the peripheral and central nervous system (CNS) of the human body, and its receptors are also expressed in the pain pathways. CGRP participates in the transmission of pain signals from the periphery to the CNS and plays a key role in pain regulation, which is related to the pathogenesis of a variety of pain diseases and related syndromes, including somatic pain, visceral pain, neuropathic pain, inflammatory pain, and migraine. Katacalcin mainly exists as a peptide that can effectively lower plasma calcium, and its effect of lowering serum calcium levels is almost the same as that of calcitonin. CALCA gene polymorphism is associated with a variety of diseases, including reflex sympathetic dystrophy syndrome, complex regional pain syndrome, ischemic stroke, Parkinson's disease, ovarian cancer, bone mineral density, migraine, schizophrenia, bipolar disorder, and primary hypertension [1-5]. CALCA is a potential target for new therapies for a variety of diseases. Currently, various CALCA antagonists are being developed for the treatment of migraine and primary hypertension, and research on targeting CALCA for diseases such as Alzheimer's disease and Parkinson's disease is also ongoing [6-7].
This strain is a humanized mouse model of the Calca gene. Using gene editing technology, the base sequence of the mouse Calca gene from the start codon to the 3’UTR region was replaced by the corresponding sequence in the human CALCA gene, while the 5’UTR region of the mouse Calca gene was retained. Homozygous B6-hCALCA mice are viable and fertile and can be used to study the mechanisms of various physiological and pathological processes such as blood pressure regulation, cell proliferation, cell apoptosis, vascular biology, physiological bone marrow production, inflammation, tumor growth, and research on CALCA-targeted migraine drugs and therapies.
Reference
Guldiken B, Sipahi T, Tekinarslan R, et al. Calcitonin gene related peptide gene polymorphism in migraine patients. The Canadian Journal of Neurological Sciences. 2013;40:722-725.
Xin-lin L, Tian-lun Y, Xiao-ping C, et al. Association of CALCA genetic polymorphism with essential hypertension. Chinese Medical Journal-Peking. 2008;121(15):1407-1410.
Alkanli N, Sipahi T, Ay A. Calcitonin related polypeptide alpha gene polymorphisms according to plasma total homocysteine levels in ischemic stroke patients of Trakya Region. Biotechnology & Biotechnological Equipment. 2017;31(6):1184-1191.
Goodman MT, Ferrell R, McDuffie K. Calcitonin gene polymorphism CALCA-624 (T/C) and ovarian cancer. Environmental and Molecular Mutagenesis. 2005;46:53-58.
Buervenich S, Xiang F, Sydow O. Identification of four novel polymorphisms in the calcitonin/a-CGRP (CALCA) gene and an investigation of their possible associations with Parkinson disease schizophrenia, and manic depression. Human Mutation. 2001;17(5):435-436.
Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev. 2023 Apr 1;103(2):1565-1644.
Singh Y, Gupta G, Shrivastava B, Dahiya R, Tiwari J, Ashwathanarayana M, Sharma RK, Agrawal M, Mishra A, Dua K. Calcitonin gene-related peptide (CGRP): A novel target for Alzheimer's disease. CNS Neurosci Ther. 2017 Jun;23(6):457-461.
Strain Strategy
The sequence from the ATG start codon to the 3’UTR region (including) of the endogenous Calca gene in mice was replaced by the corresponding sequence in the human CALCA gene, while the 5’UTR region of the mouse Calca gene was retained.
Figure 1. Schematic representation of the gene editing strategy for generating B6-hCALCA mice.
Application Area
Discovery and screening of migraine drugs and therapies;
Evaluation of the efficacy and safety of migraine drugs and therapies;
Research on vascular biology and blood pressure regulation;
Research on cell proliferation and apoptosis;
Research on tumor growth inhibition and inflammation;
Research on the generation and differentiation of hematopoietic stem/progenitor cells.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.